Enzalutamide Patent Expiration
Enzalutamide is Used for treating non-metastatic castration-sensitive prostate cancer patients with biochemical recurrence at high risk for metastasis. It was first introduced by Astellas Pharma Us Inc
Enzalutamide Patents
Given below is the list of patents protecting Enzalutamide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xtandi | US12161628 | Combination therapy | Feb 23, 2037 | Astellas |
| Xtandi | US11839689 | Formulations of enzalutamide | Sep 11, 2033 | Astellas |
| Xtandi | US7709517 | Diarylhydantoin compounds | Aug 13, 2027 | Astellas |
| Xtandi | US8183274 | Treatment of hyperproliferative disorders with diarylhydantoin compounds | Aug 24, 2026 | Astellas |
| Xtandi | US9126941 | Treatment of hyperproliferative disorders with diarylhydantoin compounds | May 15, 2026 | Astellas |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Enzalutamide's patents.
Latest Legal Activities on Enzalutamide's Patents
Given below is the list recent legal activities going on the following patents of Enzalutamide.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent eGrant Notification | 12 Dec, 2023 | US11839689 |
| Patent Issue Date Used in PTA Calculation Critical
| 12 Dec, 2023 | US11839689 |
| Recordation of Patent eGrant | 12 Dec, 2023 | US11839689 |
| Recordation of Patent Grant Mailed Critical
| 12 Dec, 2023 | US11839689 |
| Mail Patent eGrant Notification | 12 Dec, 2023 | US11839689 |
| Email Notification Critical
| 12 Dec, 2023 | US11839689 |
| Email Notification Critical
| 23 Nov, 2023 | US11839689 |
| Issue Notification Mailed Critical
| 22 Nov, 2023 | US11839689 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 Nov, 2023 | US8183274(Litigated) |
| Application Is Considered Ready for Issue Critical
| 09 Nov, 2023 | US11839689 |
Enzalutamide's Family Patents
